Peptides for Endometriosis — Evidence Review
Endometriosis is an inflammatory and estrogen-driven disease with no cure and limited symptomatic options. Standard care leans on hormonal suppression (combined oral contraceptives, GnRH agonists,…
Endometriosis is an inflammatory and estrogen-driven disease with no cure and limited symptomatic options. Standard care leans on hormonal suppression (combined oral contraceptives, GnRH agonists, progestins) and surgical excision. Peptides have not been studied directly in randomized endometriosis trials. The interest in peptide therapy here comes from extrapolating anti-inflammatory and tissue-repair data — much of it from animal models — to a disease where the inflammatory component is well-characterized.
This guide covers the peptides with the most plausible mechanistic case and the ones with no human data despite community claims.
Peptides with the most plausible mechanistic case
Tesamorelin
Tesamorelin is FDA-approved for HIV-associated lipodystrophy and reduces visceral adipose tissue. Its relevance to endometriosis is indirect — visceral adiposity correlates with elevated estrogen production via aromatase activity in adipose, and weight reduction can reduce circulating estrogen in patients with high BMI. There are no endometriosis-specific tesamorelin trials. This is mechanistic extrapolation, not validated therapy.
BPC-157
BPC-157 has a substantial animal-model literature on tissue repair, anti-inflammatory action, and gut healing. Several rodent studies report attenuation of NSAID-induced enteropathy and ulcer healing — relevant because chronic NSAID use is common in endometriosis pain management and contributes to GI side effects. There are zero completed human trials for BPC-157 in any indication. The endometriosis-specific case is theoretical: pelvic inflammatory tissue may benefit from a peptide with anti-inflammatory and angiogenic-modulating effects, but pro-angiogenic action is also a theoretical concern in a disease defined by ectopic vascularized lesions.
KPV (Lysine-Proline-Valine)
KPV is a tripeptide fragment of α-MSH with anti-inflammatory action via the melanocortin pathway. It has been studied in inflammatory bowel disease models with promising preclinical results. No endometriosis-specific data exists. The pelvic-pain-and-inflammation overlap with IBD is the rationale community discussions cite.
Peptides with weaker cases
Cerebrolysin
Sometimes mentioned in chronic-pain contexts via neuroinflammation pathways. There are no endometriosis trials. We mention it because it appears in patient forums, not because the evidence supports use.
What the evidence does not support
- Any claim that a peptide treats endometriosis "at the source" — the disease has hormonal, immune, and genetic components that no peptide currently studied addresses comprehensively.
- BPC-157 as a "lesion shrinker" — the angiogenesis profile actually argues against this.
- Use as a substitute for hormonal therapy or surgical management.
Where to source
If a clinician approves an adjunctive peptide trial, vendor quality varies meaningfully:
- BPC-157 vendor rankings — 12 vendors ranked, top 3 have purity ≥99.0%
- Tesamorelin vendor rankings — limited; tesamorelin compounding is regulatorily constrained
What we don't know
- Whether anti-inflammatory peptides modify endometriosis lesion progression in humans
- Long-term safety in reproductive-age patients (most peptides covered lack pregnancy-safety data)
- Interaction effects with hormonal suppression (GnRH agonists, progestins)
- Whether any peptide affects endometriosis-associated infertility outcomes
Methodology
Read the full methodology for our scoring rubric and source-data attribution.
This page is educational. It is not medical advice. Endometriosis management is a multidisciplinary clinical decision that should be made with a gynecologist or pain specialist familiar with the disease.